Reports FY24 revenue $32M vs $31.3M last year. David Portnoy, Cryo-Cell’s (CCEL) Chairman of the Board and Co-CEO remarked, “The Company’s 2024 fiscal results were impacted by continued investments related to the Duke License Agreement. We expect reduced expenditures related thereto this year; however, higher legal expenses are anticipated in fiscal year 2025 versus fiscal year 2024.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks